恩度联合化疗治疗晚期非小细胞肺癌的临床研究

目的：观察恩度（重组人血管内皮抑素）联合含铂化疗方案治疗晚期非小细胞肺癌的近期疗效和安全性,并与单纯含铂化疗方案比较。方法：依照入选标准,选择60例晚期NSCLC住院患者,分恩度联合化疗组28例和单纯化疗组32例,观察有效率（RR）、疾病控制率（DCR）、生活质量改善情况及不良反应。结果：恩度联合化疗组和单纯化疗组的有效率分别为28.57%和28.13%,无统计学差异（P〉0.05）;疾病控制率分别为96.43%和93.75%,无统计学差异（P〉0.05）。治疗后两组ECOG评分均较治疗前明显降低,具有统计学差异（P〈0.05）,但两组间比较,无统计学差异（P〉0.05）。恩度联合化疗组的临床症状缓解率较单纯化疗组高：咳嗽缓解率分别为80%和71.43%、气短缓解率分别为78.57%和75%、咯血缓解率分别为90%和81.82%、疼痛缓解率分别为75%和71.43%,但无统计学差异（P〉0.05）。两组的主要不良反应均为恶心/呕吐、疲乏及骨髓抑制,骨髓抑制以白细胞、中性粒细胞减少为主,患者均可耐受,两组间不良反应发生率均无统计学差异（P〉0.05）。结论：恩度与含铂化疗联合应用,未改善近期疗效,未增加不良反应,但具有提高生活质量的趋势,值得临床进一步研究。

Research of endostar combined with platinum-based chemotherapy for advanced non-small cell lung cancer

Objective： To investigate the short-term effects and safety of Endostar（recombinant human endostatin） combined with platinum-based chemotherapy for advanced non-small cell lung cancer（NSCLC） and to compare with platinum-based chemotherapy alone. Methods： Total of 60 advanced NSCLC inpatients were selected and divided into two groups：28 patients treated with Endostar plus platinum-based chemotherapy and 32 patients treated with platinum-based chemotherapy alone.And the response rate（RR）,disease control rate（DCR）,quality of life improvement and side reactions were evaluated. Results： Endostar plus cheotherapy compare to chemotherapy alone,the RR were 28.57% and 28.13%（P0.05）;the DCR were 96.43% and 93.75%（P0.05）.After therapy, the ECOG of two groups all reduced（P0.05）,but no statistical difference between two groups（P0.05）.The relief rates of clinical symptoms of Endostar plus chemotherapy were higher than chemotherapy alone：the relief rates of cough were 80.25% and 71.43%;the relief rates of short breath were 78.57% and 75%;the relief rates of hemoptysis were 90% and 81.82%;the relief rates of pain were 75% and 71.43%,but no statistical differences existed（P0.05）.The main side reactions of two groups were nausea/vomiting,fatigue, bone marrow depression and so on.Leukopenia and granulopenia were predominant in bone marrow depression.All patients were capable of tolerating the side reactions. Conclusion： The combination of Endostar with platinum-based chemotherapy can not improve curative effect,and side reactions.But it has a tendency of improving quality of life.